CompletedPhase 2NCT02400463
A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
Studying Hemophagocytic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Michigan Rogel Cancer Center
- Principal Investigator
- Ryan Wilcox, M.D., D.CInt Med-Hematology/Oncology - Faculty and Staff
- Intervention
- Ruxolitinib(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2020
Study locations (1)
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02400463 on ClinicalTrials.govOther trials for Hemophagocytic syndrome
Additional recruiting or active studies for the same condition.